At the time of writing, Viridian Therapeutics Inc [VRDN] stock is trading at $19.03, up 1.60%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRDN shares have gain 6.61% over the last week, with a monthly amount drifted -3.84%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Viridian Therapeutics Inc [NASDAQ: VRDN] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $27 from $37. On September 11, 2024, Needham reiterated its Buy rating and revised its price target to $38 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $29 on June 11, 2024. Goldman initiated its recommendation with a Buy and recommended $23 as its price target on June 06, 2024. Ladenburg Thalmann downgraded its rating to Neutral for this stock on May 09, 2024. In a note dated May 09, 2024, B. Riley Securities downgraded an Neutral rating on this stock and revised its target price from $25 to $20.
For the past year, the stock price of Viridian Therapeutics Inc fluctuated between $11.40 and $27.20. Currently, Wall Street analysts expect the stock to reach $22.75 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $19.03 at the most recent close of the market. An investor can expect a potential return of 19.55% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
According to Viridian Therapeutics Inc [NASDAQ:VRDN], the company’s sales were 0.30M for trailing twelve months, which represents an 19.44% jump. Gross Profit Margin for this corporation currently stands at -20.48% with Operating Profit Margin at -937.23%, Pretax Profit Margin comes in at -851.27%, and Net Profit Margin reading is -851.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.45 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.33 points at the first support level, and at 17.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.59, and for the 2nd resistance point, it is at 20.15.
Ratios To Look Out For
It is important to note that Viridian Therapeutics Inc [NASDAQ:VRDN] has a current ratio of 18.55. In addition, the Quick Ratio stands at 18.55 and the Cash Ratio stands at 4.84. Considering the valuation of this stock, the price to sales ratio is 5105.22, the price to book ratio is 2.91.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 1.6 million shares on Sep 13 ’24.
